No annual revenue total was found in Atrium Therapeutics, Inc.'s SEC filings.
Atrium Therapeutics, Inc. (RNA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $263.9 million in cash and investments and $1.7 million in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$262.22M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2093101
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K/A |
Amended current report
Other events
|
Oct 9, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 8, 2026 | Oct 7, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
All 55 Atrium Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.